Cargando…
Strategies to inhibit FGFR4 V550L-driven rhabdomyosarcoma
BACKGROUND: Rhabdomyosarcoma (RMS) is a paediatric cancer driven either by fusion proteins (e.g., PAX3-FOXO1) or by mutations in key signalling molecules (e.g., RAS or FGFR4). Despite the latter providing opportunities for precision medicine approaches in RMS, there are currently no such treatments...
Autores principales: | Fiorito, Elisa, Szybowska, Patrycja, Haugsten, Ellen M., Kostas, Michal, Øy, Geir F., Wiedlocha, Antoni, Singh, Sachin, Nakken, Sigve, Mælandsmo, Gunhild M., Fletcher, Jonathan A., Meza-Zepeda, Leonardo A., Wesche, Jørgen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681859/ https://www.ncbi.nlm.nih.gov/pubmed/36097178 http://dx.doi.org/10.1038/s41416-022-01973-6 |
Ejemplares similares
-
Negative Regulation of FGFR (Fibroblast Growth Factor Receptor) Signaling
por: Szybowska, Patrycja, et al.
Publicado: (2021) -
Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
por: Szybowska, Patrycja, et al.
Publicado: (2019) -
Fibroblast Growth Factor 2 Conjugated with Monomethyl
Auristatin E Inhibits Tumor Growth in a Mouse Model
por: Krzyscik, Mateusz A., et al.
Publicado: (2021) -
Roles of the FGF-FGFR Signaling System in Cancer Development and Inflammation
por: Wiedlocha, Antoni, et al.
Publicado: (2021) -
Efficacy and Selectivity of FGF2-Saporin Cytosolically Delivered by PCI in Cells Overexpressing FGFR1
por: Vikan, Aurora K., et al.
Publicado: (2021)